文献速递神经肿瘤

胶质母细胞瘤驱动基因与关键通路的鉴定显示JNJ-7706621是一种新型抗胶质母细胞瘤药物

Identification of Driver Genes and Key Pathways of Glioblastoma Shows JNJ-7706621 as a Novel Antiglioblastoma Drug.
PubMed 文献 · World Neurosurg · 2017-10-06

该研究通过生物信息学分析GSE42656、GSE50161和GSE86574基因表达谱筛选胶质母细胞瘤差异表达基因,鉴定出AURKA、NDC80、KIF4A和NUSAP1为枢纽基因,并验证其表达与预后相关;体外实验显示JNJ-7706621通过诱导凋亡抑制胶质母细胞瘤细胞活力、增殖和迁移,提示其可能成为潜在治疗药物。

要点

  • AURKA、NDC80、KIF4A和NUSAP1在胶质母细胞瘤细胞中显著高表达。
  • 低表达AURKA、NDC80、KIF4A和NUSAP1的患者预后良好。
  • JNJ-7706621体外抑制胶质母细胞瘤细胞活力、增殖和迁移并诱导凋亡。

核心结论

  • AURKA、NDC80、KIF4A和NUSAP1在胶质母细胞瘤细胞中显著高于人正常胶质细胞表达,低表达这4个基因的患者预后良好,JNJ-7706621是治疗胶质母细胞瘤患者的潜在药物。

研究设计与样本

  • 从基因表达综合数据库获取GSE42656、GSE50161和GSE86574的基因表达谱,比较胶质母细胞瘤组织与正常组织的差异表达基因,并进行基因本体、京都基因与基因组百科全书分析和蛋白质-蛋白质相互作用网络分析。
  • 采用定量逆转录聚合酶链反应和生存曲线分析验证枢纽基因表达与预后的相关性。
  • 体外采用MTT实验、集落形成实验、划痕实验和流式细胞术验证JNJ-7706621的治疗效果。

主要发现

  • 蛋白质-蛋白质相互作用网络分析鉴定出AURKA、NDC80、KIF4A和NUSAP1为枢纽基因。
  • 定量逆转录聚合酶链反应检测到这些基因在人正常胶质细胞与胶质母细胞瘤细胞间差异表达(P < 0.05)。
  • 生存曲线分析显示低表达AURKA、NDC80、KIF4A和NUSAP1的患者预后显著良好(P < 0.05)。
  • 体外实验显示JNJ-7706621通过诱导胶质母细胞瘤细胞凋亡抑制其细胞活力、增殖和迁移。

关键数值与推荐

  • 差异表达基因的鉴定基于GSE42656、GSE50161和GSE86574基因表达谱中胶质母细胞瘤组织与正常组织的比较。
  • 枢纽基因AURKA、NDC80、KIF4A和NUSAP1经蛋白质-蛋白质相互作用网络分析确定。
  • 定量逆转录聚合酶链反应验证差异表达的统计学显著性为P < 0.05。
  • 生存曲线分析显示低表达AURKA、NDC80、KIF4A和NUSAP1患者预后良好的统计学显著性为P < 0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study is to identify novel targets of diagnosis, therapy, and prognosis for glioblastoma, as well as to verify the therapeutic effect of JNJ-7706621 regarding glioblastoma. METHODS: The gene expression profiles of GSE42656, GSE50161, and GSE86574 were obtained respectively from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) were identified with comparison between gene expression profiles of the glioblastoma tissues and normal tissues. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and protein-protein interaction (PPI) network analyses were performed. Quantitative reverse transcription polymerase chain reaction and survival curve analysis were also conducted to verify the correlation between expression of hub genes and prognosis. Moreover, in vitro, MTT assay, colony-forming assay, the scratch assay, and flow cytometry were performed to verify the therapeutic effect of JNJ-7706621. RESULTS: AURKA, NDC80, KIF4A, and NUSAP1 were identified as hub genes after PPI network analysis. Differential expression of those genes was detected between human normal glial cells and glioblastoma cells by quantitative reverse transcription polymerase chain reaction (P < 0.05), and the survival curve analysis showed that the patients with low expression of gene AURKA, NDC80, KIF4A, and NUSAP1 had a significant favorable prognosis (P < 0.05). In vitro assays showed that JNJ-7706621 inhibited glioblastoma cellular viability, proliferation, and migration via inducing glioblastoma cells apoptosis. CONCLUSIONS: AURKA, NDC80, KIF4A, and NUSAP1 were significantly more highly expressed in glioblastoma cells than in human normal glial cell. Patients with low expression of those 4 genes had a favorable prognosis. JNJ-7706621 was a potential drug in treatment of patients with glioblastoma.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhong S, Wu B, Dong X, et al. Identification of Driver Genes and Key Pathways of Glioblastoma Shows JNJ-7706621 as a Novel Antiglioblastoma Drug. World Neurosurg. 2017. PMID: 28989042. doi:10.1016/j.wneu.2017.09.176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。